AU2002221112A1 - Method of estimating risk of the expression of side effect caused by the administration of compound metabolized, either per se or as its metabolic intermediate,by ugt1a1 enzyme - Google Patents

Method of estimating risk of the expression of side effect caused by the administration of compound metabolized, either per se or as its metabolic intermediate,by ugt1a1 enzyme

Info

Publication number
AU2002221112A1
AU2002221112A1 AU2002221112A AU2111202A AU2002221112A1 AU 2002221112 A1 AU2002221112 A1 AU 2002221112A1 AU 2002221112 A AU2002221112 A AU 2002221112A AU 2111202 A AU2111202 A AU 2111202A AU 2002221112 A1 AU2002221112 A1 AU 2002221112A1
Authority
AU
Australia
Prior art keywords
administration
expression
irinotecan
adverse drug
drug reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002221112A
Other languages
English (en)
Inventor
Yu-Uichi Ando
Yoshinori Hasegawa
Kaoru Shimokata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nagoya Industrial Science Research Institute
Original Assignee
Nagoya Industrial Science Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nagoya Industrial Science Research Institute filed Critical Nagoya Industrial Science Research Institute
Publication of AU2002221112A1 publication Critical patent/AU2002221112A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2002221112A 2000-12-12 2001-12-10 Method of estimating risk of the expression of side effect caused by the administration of compound metabolized, either per se or as its metabolic intermediate,by ugt1a1 enzyme Abandoned AU2002221112A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-376756 2000-12-12
JP2000376756 2000-12-12
PCT/JP2001/010813 WO2002048400A1 (fr) 2000-12-12 2001-12-10 Procede d'estimation du risque de l'expression d'effets secondaires causes par l'administration de compose metabolise, soit automatiquement, soit comme intermediaire metabolique, par l'enzyme ugt1a1

Publications (1)

Publication Number Publication Date
AU2002221112A1 true AU2002221112A1 (en) 2002-06-24

Family

ID=18845576

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002221112A Abandoned AU2002221112A1 (en) 2000-12-12 2001-12-10 Method of estimating risk of the expression of side effect caused by the administration of compound metabolized, either per se or as its metabolic intermediate,by ugt1a1 enzyme

Country Status (10)

Country Link
US (4) US20040058363A1 (ja)
EP (1) EP1352970B1 (ja)
JP (2) JP4447835B2 (ja)
KR (2) KR101651391B1 (ja)
CN (1) CN100374575C (ja)
AT (1) ATE469966T1 (ja)
AU (1) AU2002221112A1 (ja)
DE (1) DE60142309D1 (ja)
ES (1) ES2346848T3 (ja)
WO (1) WO2002048400A1 (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395481B1 (en) * 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter
WO2002059375A2 (en) * 2001-01-26 2002-08-01 University Of Chicago Determination of ugt2b7 gene polymorphisms for predicting ugt2b7 substrate toxicity and for optimising drug dosage
AU2003257344A1 (en) * 2002-09-20 2004-04-08 Universite Laval Method for determining the predisposition of patients to toxicity or lack of efficacy of a drug
US20040203034A1 (en) * 2003-01-03 2004-10-14 The University Of Chicago Optimization of cancer treatment with irinotecan
JP2006526412A (ja) 2003-05-30 2006-11-24 ユニバーシティ オブ シカゴ イリノテカン毒性を推定する方法および組成物
CA2541097A1 (en) * 2003-10-06 2005-05-06 Novartis Ag Biomarkers for the prediction of drug-induced diarrhoea
US20090247475A1 (en) * 2004-03-05 2009-10-01 The Regents Of The University Of California Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies
WO2007055261A1 (ja) * 2005-11-10 2007-05-18 The New Industry Research Organization Ｕｇｔ１ａ１遺伝子多型の検査法
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
GB2432365A (en) * 2005-11-18 2007-05-23 Dxs Ltd A nucleic acid molecule for detecting polymorphisms in the UGT1A1 promoter
JP4884899B2 (ja) * 2006-09-19 2012-02-29 東洋鋼鈑株式会社 イリノテカンの副作用の発生危険度を判定する方法およびそのためのキット
CN102168140B (zh) * 2006-11-30 2013-10-23 爱科来株式会社 Ugt1a1基因扩增用引物对、含有其的ugt1a1基因扩增用试剂及其用途
KR200452078Y1 (ko) * 2009-03-10 2011-01-28 주식회사 디아이디 벽지샘플북의 손잡이
JP2011250726A (ja) * 2010-06-01 2011-12-15 Toyo Kohan Co Ltd イリノテカンの副作用の発生危険度を判定する方法及びそのためのキット
CN102816858B (zh) * 2012-09-06 2014-02-19 上海源奇生物医药科技有限公司 一种检测ugt1a1基因型的引物和探针、及其试剂盒
JP6324828B2 (ja) * 2014-07-07 2018-05-16 株式会社日立製作所 薬効分析システム及び薬効分析方法
WO2016132736A1 (ja) 2015-02-17 2016-08-25 国立大学法人山口大学 イリノテカンによる副作用の発生リスクの予測を補助する方法
CN107043808A (zh) * 2017-01-19 2017-08-15 上海赛安生物医药科技有限公司 Ugt1a1基因多态性检测引物肽核酸及其试剂盒
CN109371127A (zh) * 2018-10-22 2019-02-22 江苏美因康生物科技有限公司 一种同时快速检测ugt1a1*6型与ugt1a1*28型基因多态性的试剂盒及方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
WO1997032042A2 (en) * 1996-03-01 1997-09-04 The University Court Of The University Of Dundee Drug trial assay system
DK1071710T4 (da) * 1998-04-15 2011-12-12 Merck Serono Biodevelopment Genomisk sekvens for 5-lipoxygenase-aktiveringsproteinet (FLAP), polymorfe markører deri og fremgangsmåder til påvisning af astma
WO1999057322A2 (en) * 1998-05-07 1999-11-11 Axys Pharmaceuticals, Inc. Genotyping the human udp-glucuronosyltransferase 1 (ugt1) gene
US6395481B1 (en) * 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter

Also Published As

Publication number Publication date
WO2002048400A1 (fr) 2002-06-20
JPWO2002048400A1 (ja) 2004-04-15
ES2346848T3 (es) 2010-10-21
CN100374575C (zh) 2008-03-12
KR20160031023A (ko) 2016-03-21
JP2009195247A (ja) 2009-09-03
EP1352970A1 (en) 2003-10-15
KR101651391B1 (ko) 2016-08-25
US20070082357A1 (en) 2007-04-12
DE60142309D1 (de) 2010-07-15
US20040058363A1 (en) 2004-03-25
KR101651287B1 (ko) 2016-08-26
CN1547613A (zh) 2004-11-17
US20110151474A1 (en) 2011-06-23
JP4616919B2 (ja) 2011-01-19
EP1352970B1 (en) 2010-06-02
ATE469966T1 (de) 2010-06-15
JP4447835B2 (ja) 2010-04-07
US20090263818A1 (en) 2009-10-22
KR20030053064A (ko) 2003-06-27
EP1352970A4 (en) 2004-08-25

Similar Documents

Publication Publication Date Title
AU2002221112A1 (en) Method of estimating risk of the expression of side effect caused by the administration of compound metabolized, either per se or as its metabolic intermediate,by ugt1a1 enzyme
YU74500A (sh) Novi derivat 3-aril-2-hidroksipropionske kiseline (i)
WO1999057322A3 (en) Genotyping the human udp-glucuronosyltransferase 1 (ugt1) gene
WO2001090122A3 (en) Haplotypes of the ctla4 gene
WO2005037987A3 (en) Isolated nucleotide sequences responsible for the tomato high pigment-1 mutant phenotypes (hp-1 and hp-1w) and uses thereof
WO2002026768A3 (en) Haplotypes of the por gene
WO2002038589A3 (en) Haplotypes of the cyp2d6 gene
WO2002006294A3 (en) Haplotypes of the mmp13 gene
Mani UGT1A1 polymorphism predicts irinotecan toxicity: evolving proof
WO2001079230A3 (en) Haplotypes of the ugt1a1 gene
WO2002026764A3 (en) Haplotypes of the ccr6 gene
WO2002008425A3 (en) Haplotypes of the adrb3 gene
WO2000047776A3 (en) Insulin-family homolog localized to chromosome 1
WO2001023603A3 (en) Human fmo3 gene mutations and polymorphisms, and uses thereof
WO2002012498A3 (en) Haplotypes of the isl1 gene
WO2001077363A3 (en) Haplotypes of the impdh2 gene
WO2002026766A3 (en) Haplotypes of the sstr4 gene
WO2002053579A3 (en) Haplotypes of the fmo2 gene
WO2002022652A8 (en) Haplotypes of the slc18a2 gene
WO2002012562A3 (en) Haplotypes of the pla2g1b gene
WO2002038587A3 (en) Haplotypes of the grm8 gene
WO2001090118A3 (en) Haplotypes of the edn2 gene
WO2002020556A3 (en) Haplotypes of the gpr68 gene
WO2001087904A3 (en) Haplotypes of the gpr4 gene
WO2002002580A3 (en) Haplotypes of the etfb gene